Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NFT6

UPID:
DBF4B_HUMAN

ALTERNATIVE NAMES:
Activator of S phase kinase-like protein 1; Chiffon homolog B; Dbf4-related factor 1

ALTERNATIVE UPACC:
Q8NFT6; D3DX56; Q8TEX0; Q96B19; Q9H912

BACKGROUND:
The Protein DBF4 homolog B, with alternative names such as Activator of S phase kinase-like protein 1, Chiffon homolog B, and Dbf4-related factor 1, is central to cell cycle progression. It activates CDC7 kinase activity, essential for DNA replication and cell proliferation. The specific phosphorylation of MCM2 subunit at Ser-40 by the CDC7-DBF4B complex underscores its role in initiating DNA replication during the S and M phases.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Protein DBF4 homolog B offers a promising avenue for developing novel therapeutic approaches in conditions characterized by abnormal cell growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.